Cargando…

Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience

Breast and prostate cancer have a propensity to metastasize to bones and cause osteolysis and abnormal new bone formation. Metastases locally disrupt normal bone remodeling. Although metastases from prostate cancer have been classified as osteoblastic based on the radiographic appearance of the lesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasulova, Nigora, Lyubshin, Vladimir, Arybzhanov, Dauranbek, Krylov, Valery, Khodjibekov, Marat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745628/ https://www.ncbi.nlm.nih.gov/pubmed/23961251 http://dx.doi.org/10.4103/1450-1147.113942

Ejemplares similares

Optimal Timing of Bisphosphonate Administration in Combination with Samarium-153 Oxabifore in the Treatment of Painful Metastatic Bone Disease
por: Rasulova, Nigora, et al.
Publicado: (2013)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Strategy for Bone Metastases Treatment in Patients with Impending Cord Compression or Vertebral Fractures: A Pilot Study
por: Rasulova, N., et al.
Publicado: (2011)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
por: Cadieux, Benoit, et al.
Publicado: (2022)

A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva(®)) Related Osteonecrosis of the Jaw: A Retrospective Study
por: Assili, Zineb, et al.
Publicado: (2021)

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
por: Ding, Yanhua, et al.
Publicado: (2023)

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [$^{153}$Sm]Sm-DOTA-TATE
por: Vermeulen, Koen, et al.
Publicado: (2022)

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [(153)Sm]Sm-DOTA-TATE
por: Vermeulen, Koen, et al.
Publicado: (2022)

The influence of Sm-153 therapy on bone marrow function
por: Małkowski, Bogdan, et al.
Publicado: (2016)

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2007)

Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism with (153)Sm-EDTMP
por: Kassi, Eva, et al.
Publicado: (2017)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Molecular genetic tests in survival factors in patients with NSCLC in the clinical practice of Kazakhstan
por: Yessentayeva, Suriya Ye., et al.
Publicado: (2021)

Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis
por: Ayati, Narjess, et al.
Publicado: (2013)

Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
por: Wendt, Richard E., et al.
Publicado: (2022)

Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma
por: Keskin, Onur, et al.
Publicado: (2015)

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
por: Van de Voorde, Michiel, et al.
Publicado: (2021)

Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan
por: Ramachandran, Krishnakumar, et al.
Publicado: (2011)

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
por: Van de Voorde, Michiel, et al.
Publicado: (2021)

Preliminary Clinical Experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Toxicity of Therapy with Sm-153-EDTMP: To What Extend can it be Related to the Tumor Type?
por: Świętaszczyk, Cyprian, et al.
Publicado: (2016)

Development of (153)Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI
por: Gholami, Amir, et al.
Publicado: (2016)

Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
por: Focaccia, Marco, et al.
Publicado: (2021)

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
por: Kairemo, Kalevi, et al.
Publicado: (2015)

Comparative Therapeutic Efficacy of (153)Sm-EDTMP and (177)Lu-EDTMP for Bone Pain Palliation in Patients with Skeletal Metastases: Patients’ Pain Score Analysis and Personalized Dosimetry
por: Sharma, Sarika, et al.
Publicado: (2017)

Preparation and Quality Control of the [(153)Sm]-Samarium Maltolate Complex as a Lanthanide Mobilization Product in Rats
por: Naseri, Zohreh, et al.
Publicado: (2011)

RADIOACTIVE CEMENT OF PMMA AND HAP-Sm-153, Ho-166, OR RE-188 FOR BONE METASTASIS TREATMENT
por: Montaño, Carlos Julio, et al.
Publicado: (2019)

Monoclonal antibody desensitization in a patient with a generalized urticarial reaction following denosumab administration
por: Gutiérrez-Fernández, D., et al.
Publicado: (2015)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters
por: Abe, Ichiro, et al.
Publicado: (2019)

Radiation Safety Considerations in the Treatment of Canine Skeletal Conditions Using (153)Sm, (90)Y, and (117m)Sn
por: Wendt, Richard E., et al.
Publicado: (2020)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

Effects of low-dose capecitabine on Samarium-153-EDTMP therapy for painful bone metastases
por: Barai, Sukanta, et al.
Publicado: (2015)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023)

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Brown-Glaberman, Ursa, et al.
Publicado: (2012)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
por: Li, Wei, et al.
Publicado: (2023)

Observed Influence of Nitroglycerine on Myocardial Perfusion Scintigraphy in Patients with Multiple Vessel Coronary Artery Disease and Well-Developed Collaterals
por: Rasulova, Nigora, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_onr6s2orqf6fbco403vbe27deu